Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

CTSO


Top 10 Correlated ETFs

CTSO


Top 10 Correlated Stocks

CTSO


In the News

06:20 29 Nov 2022 CTSO

CytoSorbents Corporation (CTSO) Q3 2022 Earnings Call Transcript

CytoSorbents Corporation (NASDAQ:CTSO ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Michelle Almonte - Executive Assistant to CEO Phillip Chan - Chief Executive Officer Kathleen Bloch - Chief Financial Officer Christian Steiner - EVP of Sales and Marketing and Managing Director of CytoSorbents Europe GmbH Efthymios Deliargyris - Chief Medical Officer Vincent Capponi - Chief Operating Officer and President Christopher Cramer - VP of Business Development Conference Call Participants Zachary Weiner - Jefferies Sean Lee - H.C. Wainwright Operator Good day, and welcome to the CytoSorbents Corporation Third Quarter 2022 Earnings Conference Call.

09:49 29 Nov 2022 CTSO

CytoSorbents (CTSO) Reports Q3 Loss, Misses Revenue Estimates

CytoSorbents (CTSO) delivered earnings and revenue surprises of -75% and 9.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

07:00 29 Nov 2022 CTSO

CytoSorbents to Report Third Quarter 2022 Operating and Financial Results

PRINCETON, N.J. , Oct. 27, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2022 operating and financial results after the market close on Thursday, November 3, 2022.

11:03 29 Nov 2022 CTSO

Cytosorbents Corporation's (CTSO) CEO Phillip Chan on Q2 2022 Results - Earnings Call Transcript

Cytosorbents Corporation (NASDAQ:CTSO ) Q2 2022 Earnings Conference Call August 2, 2022 4:30 PM ET Company Participants Amy Vogel – Investor Relations Phillip Chan – Chief Executive Officer Kathleen Bloch – Chief Financial Officer Christian Steiner – Executive Vice President-Sales and Marketing and Managing Director-Cytosorbents Europe GmbH Christopher Cramer – Vice President-Business Development Efthymios Deliargyris – Chief Medical Officer Vincent Capponi – Chief Operating Officer and President Mike Gibson – Principal Co-Investigator-STAR-T Conference Call Participants Zach Weiner – Jefferies Brian Kennedy – Cowen Sean Lee – H.C. Wainwright Operator Good afternoon, and welcome to Cytosorbents Second Quarter 2022 Financial and Operating Results Conference Call.

07:00 29 Nov 2022 CTSO

CytoSorbents to Report Second Quarter 2022 Operating and Financial Results

PRINCETON, N.J. , July 25, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2022 operating and financial results after the market close on August 2 nd, 2022.

07:54 29 Nov 2022 CTSO

3 Stocks Under $3 Insiders Are Aggressively Buying

The Nasdaq Composite dropped by more than 400 points on Friday. Investors, meanwhile, focused on some notable insider trades.

02:54 29 Nov 2022 CTSO

10 Top Penny Stocks To Buy In June According To These Insiders Part 1

Insiders are buying these penny stocks. The post 10 Top Penny Stocks To Buy In June According To These Insiders Part 1 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

12:11 29 Nov 2022 CTSO

Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q1 2022 Results - Earnings Call Transcript

Cytosorbents Corporation (NASDAQ:CTSO ) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Terri Anne Powers - Vice President, Investor Relations & Corporate Communications Phillip Chan - Chief Executive Officer Vincent Capponi - President & Chief Operating Officer Kathleen Bloch - Chief Financial Officer Christian Steiner - Executive Vice President, Sales & Marketing and Managing Director of Cytosorbents Europe Christopher Cramer - Vice President, Business Development Efthymios Deliargyris - Chief Medical Officer Conference Call Participants Frank Pinal - Jefferies Justin Walsh - B. Riley Securities Zach Weiner - Jefferies Priya Sachdeva - SVB Operator Good afternoon and welcome to the Cytosorbents Corp.'s First Quarter 2022 Earnings Conference Call.

09:50 29 Nov 2022 CTSO

Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q4 2021 Results - Earnings Call Transcript

Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q4 2021 Results - Earnings Call Transcript

07:00 29 Nov 2022 CTSO

CytoSorbents to Report Fourth Quarter and Full Year 2021 Operating and Financial Results

MONMOUTH JUNCTION, N.J., Feb. 8, 2022 /PRNewswire/ --  CytoSorbents Corporation  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fourth quarter and full year 2021 operating and financial results after the market close on March 8, 2022.

Financial details

Company Rating
Neutral
Market Cap
65.89M
Income
-41.35M
Revenue
10.72M
Book val./share
0.9
Cash/share
0.52
Dividend
-
Dividend %
-
Employees
221
Optionable
No
Shortable
Yes
Earnings
03 Nov 2022
P/E
-2.22
Forward P/E
-
PEG
-0.06
P/S
6.14
P/B
1.68
P/C
2.63
P/FCF
-2.26
Quick Ratio
2.72
Current Ratio
3.2
Debt / Equity
0.33
LT Debt / Equity
0.33
-
-
EPS (TTM)
-0.95
EPS next Y
-
EPS next Q
-
EPS this Y
185%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
12.24%
Revenue last 5Y
23.29%
Revenue Q/Q
-11.84%
EPS Q/Q
12%
-
-
-
-
SMA20
-14.29%
SMA50
-20.88%
SMA100
-33.94%
Inst Own
34.09%
Inst Trans
-3.14%
ROA
-66%
ROE
-81%
ROC
-0.67%
Gross Margin
-25%
Oper. Margin
-324%
Profit Margin
-386%
Payout
-
Shs Outstand
43.58M
Shs Float
37.27M
-
-
-
-
Target Price
9
52W Range
1.18-5.4
52W High
-72.6%
52W Low
+37%
RSI
41.4
Rel Volume
0.46
Avg Volume
170.88K
Volume
79.01K
Perf Week
-4.86%
Perf Month
-13.84%
Perf Quarter
-46.48%
Perf Half Y
-29.02%
-
-
-
-
Beta
0.700398
-
-
Volatility
0.05%, 0.17%
Prev Close
-9.27%
Price
1.37
Change
-7.43%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
0.550.730.771.061.11
Net income per share
-0.31-0.56-0.6-0.2-0.63
Operating cash flow per share
-0.23-0.35-0.52-0.140
Free cash flow per share
-0.29-0.4-0.57-0.190
Cash per share
0.630.730.381.841.34
Book value per share
0.370.550.112.041.61
Tangible book value per share
0.310.4701.931.61
Share holders equity per share
0.370.550.112.041.61
Interest debt per share
0.360.370.510.040.02
Market cap
209.87M227.01M159.99M407.21M135.48M
Enterprise value
202.54M214.59M163.23M336.24M83.91M
P/E ratio
-24.8-13.19-8.3-51.96-5.52
Price to sales ratio
13.8510.096.419.933.14
POCF ratio
-32.48-20.94-9.55-72.540
PFCF ratio
-25.79-18.37-8.75-55.860
P/B Ratio
20.4513.4146.815.142.16
PTB ratio
20.4513.4146.815.142.16
EV to sales
13.379.546.548.21.94
Enterprise value over EBITDA
-22.71-13.43-8.71-47.34-3.32
EV to operating cash flow
-31.35-19.8-9.74-59.90
EV to free cash flow
-24.89-17.36-8.93-46.130
Earnings yield
-0.04-0.08-0.12-0.02-0.18
Free cash flow yield
-0.04-0.05-0.11-0.020
Debt to equity
0.580.553.9200
Debt to assets
0.570.480.880.120.3
Net debt to EBITDA
0.820.78-0.179.992.04
Current ratio
2.644.322.18.124.7
Interest coverage
0-10.67-18.36-8.63-812.11
Income quality
0.760.630.870.720
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
1.021.020.980.770
Research and developement to revenue
0.270.340.480.210.38
Intangibles to total assets
0.080.080.120.050
Capex to operating cash flow
0.260.140.090.30
Capex to revenue
-0.11-0.07-0.06-0.040
Capex to depreciation
-7.69-3.89-2.61-2.540
Stock based compensation to revenue
0.220.20.110.110
Graham number
1.62.641.193.044.79
ROIC
-0.61-0.59-1.09-0.13-0.3
Return on tangible assets
-0.38-0.57-0.8-0.09-0.27
Graham Net
0.20.32-0.231.70.8
Working capital
12.89M21.73M10.97M72.3M50.61M
Tangible asset value
8.42M14.31M56.63K74.99M0
Net current asset value
6.9M12.45M-3.06M71.72M37.36M
Invested capital
0.970.594.530.010.01
Average receivables
3.68M4.55M4.81M5.16M4.84M
Average payables
2.02M2.22M2.57M2.47M2.64M
Average inventory
1.73M1.75M2.39M2.67M3.72M
Days sales outstanding
53.1463.9665.3545.9238.25
Days payables outstanding
103.6395.79132.2681.4692.68
Days of inventory on hand
52.6340.6104.7888.3157.47
Receivables turnover
6.875.715.597.959.54
Payables turnover
3.523.812.764.483.94
Inventory turnover
6.948.993.484.132.32
ROE
-0.82-1.02-5.64-0.1-0.39
Capex per share
-0.06-0.05-0.05-0.040

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-09-302021-12-312022-03-312022-06-30 2022-09-30
Revenue per share
0.22-0.250.180.170.15
Net income per share
-0.15-0.21-0.21-0.25-0.28
Operating cash flow per share
-0.10-0.19-0.18-0.15
Free cash flow per share
-0.120-0.21-0.29-0.17
Cash per share
1.411.20.990.690.52
Book value per share
1.631.441.271.090.9
Tangible book value per share
1.631.441.271.090.9
Share holders equity per share
1.631.441.271.090.9
Interest debt per share
0.310.010.310.310.31
Market cap
352.38M182.17M138.73M95.4M59.31M
Enterprise value
304.99M130.6M109.36M78.74M50.14M
P/E ratio
-13.75-4.89-3.87-2.19-1.22
Price to sales ratio
36.1-16.5617.5113.019.18
POCF ratio
-85.250-17.09-11.87-8.81
PFCF ratio
-68.410-15.47-7.5-7.96
P/B Ratio
4.992.912.52.011.52
PTB ratio
4.992.912.52.011.52
EV to sales
31.25-11.8713.810.747.76
Enterprise value over EBITDA
-49.44-13.03-12.6-7.46-9.1
EV to operating cash flow
-73.780-13.47-9.79-7.44
EV to free cash flow
-59.210-12.2-6.19-6.73
Earnings yield
-0.02-0.05-0.06-0.11-0.21
Free cash flow yield
-0.010-0.06-0.13-0.13
Debt to equity
0.1900.240.280.33
Debt to assets
0.260.30.330.330.37
Net debt to EBITDA
7.685.143.381.581.66
Current ratio
6.574.73.813.953.2
Interest coverage
0-534.69-970.62-348.6-192.49
Income quality
0.6500.910.740.55
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.8601.261.241.45
Research and developement to revenue
0.44-0.560.540.570.51
Intangibles to total assets
00000
Capex to operating cash flow
0.2500.10.580.11
Capex to revenue
-0.10-0.11-0.64-0.11
Capex to depreciation
-4.290-3.01-15.97-2.58
Stock based compensation to revenue
0.1400.120.050.21
Graham number
2.322.632.432.482.38
ROIC
-0.06-0.13-0.11-0.14-0.17
Return on tangible assets
-0.07-0.1-0.11-0.15-0.2
Graham Net
0.990.710.490.30.11
Working capital
61.68M50.61M41.18M31.09M22.26M
Tangible asset value
00000
Net current asset value
48.3M37.36M28.01M18M9.25M
Invested capital
0.190.010.250.280.34
Average receivables
5.21M4.85M4.87M5.17M5.07M
Average payables
2.74M2.47M3.48M2.13M2.24M
Average inventory
4.75M4.87M5.21M4.98M4.26M
Days sales outstanding
48.33-3751.9863.4869.09
Days payables outstanding
122.780.85190.6953.9747.02
Days of inventory on hand
165.44137.36215.18126.2470.93
Receivables turnover
1.86-2.431.731.421.3
Payables turnover
0.731.110.471.671.91
Inventory turnover
0.540.660.420.711.27
ROE
-0.09-0.15-0.16-0.23-0.31
Capex per share
-0.020-0.02-0.11-0.02

Frequently Asked Questions

What is Cytosorbents Corporation stock symbol ?

Cytosorbents Corporation is a US stock , located in Monmouth junction of New jersey and trading under the symbol CTSO

What is Cytosorbents Corporation stock quote today ?

Cytosorbents Corporation stock price is $1.37 today.

Is Cytosorbents Corporation stock public?

Yes, Cytosorbents Corporation is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap